Streamlining Saxenda Prior Authorization for Oncology Patients

The Role of Saxenda in Oncology Patient Management

While Saxenda is not an oncologic agent, it addresses comorbidities such as obesity and type 2 diabetes, which are prevalent in cancer populations. These conditions can impact treatment efficacy, surgical outcomes, and overall quality of life. Oncology practices often manage these aspects of patient care, making efficient prior authorization for supportive medications critical to comprehensive patient management.

Required Documentation for Saxenda Prior Authorization

• Confirmation of diagnosis (e.g., obesity with BMI ≥ 30 kg/m² or ≥ 27 kg/m² with weight-related comorbidity, or Type 2 Diabetes).
• Documentation of previous weight management efforts (diet, exercise, behavioral changes) if prescribed for weight loss.
• Relevant comorbidities (e.g., hypertension, dyslipidemia, prediabetes) impacting the patient's overall health and cancer treatment plan.
• Current oncology treatment regimen and any potential drug interactions or contraindications.
• Performance status (ECOG or Karnofsky score) to support the patient's fitness for medication management.
• Rationale for Saxenda use in the context of the patient's cancer diagnosis and treatment.

Common Denial Reasons for Saxenda in Oncology Populations

Denials for Saxenda in oncology patients often mirror those for general populations but are compounded by the complexity of cancer care. These can include insufficient documentation of prior weight loss attempts, failure to meet specific BMI criteria, or lack of clear medical necessity linking Saxenda to the *overall* patient care plan. Payers may also scrutinize potential drug interactions with cancer therapies or question the priority of weight management during active cancer treatment.

Klivira's Solution for Complex Prior Authorizations in Oncology

Klivira's platform is designed to navigate the intricate PA landscape inherent in oncology, extending its capabilities to supportive and comorbidity medications like Saxenda. By integrating with EMRs and payer portals, Klivira streamlines the submission process, ensuring that all necessary clinical documentation, including NCCN-compendium-aware details for cancer treatments, is accurately captured and submitted.

Streamlining Saxenda PA within Oncology Workflows

• **NCCN-aware policy logic** that guides documentation requirements for all medications, including supportive care.
• **Medical-vs-pharmacy benefit routing** to ensure Saxenda PAs are submitted through the correct channel (PBM or medical payer).
• **Concurrent PA tracking** for all medications a patient receives, including cancer therapeutics and comorbidity management.
• Automated alerts for missing documentation, reducing manual review and denial rates due to documentation gaps.
• Integration with existing EMR systems to pull relevant patient data (e.g., BMI, comorbidity diagnoses, medication lists) for PA forms.